Freedman Lori 4

What Happened
Lori Freedman, Chief Administrative and Legal Officer of Organogenesis Holdings, received multiple equity awards on February 18, 2026, totaling 361,717 shares (203,125 RSUs + 42,780 performance shares + 115,812 derivative award). These awards were granted at $0.00 per share (no purchase price). To cover tax withholding related to vesting/settlement, 14,267 shares were surrendered/disposed at $3.84 per share for total consideration of $54,785. The primary activity is receipt of awards (not an open-market purchase or sale).

Key Details

• Transaction date (reporting period): February 18, 2026; SEC filing date: February 20, 2026 (filing flagged late).
• Grants: 203,125 RSUs (F1), 42,780 shares from a 2025 performance award that vested (F2), and 115,812 shares listed as a derivative award (A). All awards show $0.00 acquisition price.
• Tax withholding: 14,267 shares disposed at $3.84 each, totaling $54,785 (transaction code F). This is a routine withholding to satisfy tax liabilities on vested awards.
• Shares owned after the transactions: not specified in the filing.
• Footnotes of note:
  • F1: RSUs vest in equal annual installments over four years beginning Feb 15, 2026.
  • F2: Shares issued upon achievement of 2025 performance milestones.
  • F3: Related option/derivative becomes exercisable in equal annual installments over four years beginning Feb 15, 2026.
• Filing timeliness: marked late (L) — delayed public disclosure can be a compliance issue but does not by itself indicate intent.

Context

• RSUs and performance-share issuances represent future rights to shares upon vesting and are common components of executive compensation; they are not immediate open-market purchases.
• The 14,267-share disposition was a tax-withholding event (routine) rather than an opportunistic sale; it reduces net shares received from the awards.
• No open-market buying or opportunistic selling by the insider is shown in this filing.